Novo Nordisk (NYSE: NVO) shareholders know all about the ups and downs of pharmaceutical stock investing. From the beginning ...

New York, New York-- (Newsfile Corp. - March 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

Novo Nordisk A/S, No. 25-cv-00713, alleges that the company and its key executives committed securities violations during the Phase 3 trial of CagriSema, known as REDEFINE-1. Investors who ...

The case, filed in the U.S. District Court for the District of New Jersey under the title Moon v. Novo Nordisk A/S, No. 25-cv-00713, alleges that the company and its key executives committed ...

Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell ...

Silence can speak volumes. That silence is even louder coming from Novo Nordisk, Europe’s most valuable company, which is still reeling from disappointing weight-loss drug results in December on ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over ...

LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...